Scholarlink

Objectives <p>This meta-analysis investigated the extent to which tranexamic acid reduces the risk of postpartum bleeding among pregnant women at high risk of postpartum hemorrhage undergoing cesarean section.</p> Methods <p>Scopus, the Cochrane Library, PubMed, and Web of Science were searched from their establishment to December 4, 2025, to identify randomized controlled trials comparing tranexamic acid with placebo for preventing postpartum hemorrhage in high-risk women undergoing cesarean section. Because of high heterogeneity, we employed a random-effects model (restricted maximum–likelihood) to pool data.</p> Results <p>Finally, 12 articles with 1240 high-risk pregnant women were included in this meta-analysis. Compared to placebo, tranexamic acid significantly reduced blood loss after cesarean delivery in high-risk pregnant women (WMD − 435.44 mL, 95% CI (-581.86, -289.01) I<sup>2</sup> = 94.71%). </p> <p>Furthermore, tranexamic acid significantly prevented the drop in hemoglobin level (WMD 1.09 g/dL, 95% CI (0.20, 1.99) I2 = 97.63%), prevented postpartum hemorrhage (RR 0.45, 95% CI (0.30, 0.70) I2 = 49.34%) and more than 1000 mL blood loss (RR 0.23, 95% CI (0.14, 0.37) I2 = 0.00%), and reduced the need for transfusion (RR 0.28, 95% CI (0.20, 0.39) I2 = 0.00%) and uterogenic agents (WMD 0.28, 95% CI (0.18, 0.46) I2 = 85.63%). The beneficial effects of tranexamic acid on the length of hospital stay (WMD − 0.46 days, 95% CI (-0.93, 0.01) I2 = 73.44%) and the length of surgery (WMD − 8.20 min, 95% CI (-17.15, 0.74) I2 = 96.28%) did not reach the threshold of statistical significance. Compared to the placebo group, nausea/vomiting was significantly more frequent in the tranexamic acid group (RR 1.89, 95% CI (1.02, 3.52) I2 = 0.00%), while dizziness (RR 1.13, 95% CI (0.32, 3.92) I2 = 16.09%) and headache (RR 1.85, 95% CI (0.48, 7.19) I2 = 25.87%) showed no significant. There was no case of thromboembolic events in either group. Exploratory subgroup analysis showed that sample size, risk of bias, mother’s body mass index (BMI), tranexamic acid dose, the timing of administration, gestational age, and the reason for being high-risk significantly affected the beneficial effects of tranexamic acid on the volume of blood loss.</p> Conclusion <p>Our findings suggest that tranexamic acid may effectively reduce bleeding among women with a high risk of postpartum hemorrhage undergoing cesarean section.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy of tranexamic acid for the prevention of postpartum hemorrhage among women at high risk of postpartum hemorrhage undergoing cesarean section: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Qian Gao,
  • Pan Li,
  • Cui Li,
  • Haining Wang

摘要

Objectives

This meta-analysis investigated the extent to which tranexamic acid reduces the risk of postpartum bleeding among pregnant women at high risk of postpartum hemorrhage undergoing cesarean section.

Methods

Scopus, the Cochrane Library, PubMed, and Web of Science were searched from their establishment to December 4, 2025, to identify randomized controlled trials comparing tranexamic acid with placebo for preventing postpartum hemorrhage in high-risk women undergoing cesarean section. Because of high heterogeneity, we employed a random-effects model (restricted maximum–likelihood) to pool data.

Results

Finally, 12 articles with 1240 high-risk pregnant women were included in this meta-analysis. Compared to placebo, tranexamic acid significantly reduced blood loss after cesarean delivery in high-risk pregnant women (WMD − 435.44 mL, 95% CI (-581.86, -289.01) I2 = 94.71%).

Furthermore, tranexamic acid significantly prevented the drop in hemoglobin level (WMD 1.09 g/dL, 95% CI (0.20, 1.99) I2 = 97.63%), prevented postpartum hemorrhage (RR 0.45, 95% CI (0.30, 0.70) I2 = 49.34%) and more than 1000 mL blood loss (RR 0.23, 95% CI (0.14, 0.37) I2 = 0.00%), and reduced the need for transfusion (RR 0.28, 95% CI (0.20, 0.39) I2 = 0.00%) and uterogenic agents (WMD 0.28, 95% CI (0.18, 0.46) I2 = 85.63%). The beneficial effects of tranexamic acid on the length of hospital stay (WMD − 0.46 days, 95% CI (-0.93, 0.01) I2 = 73.44%) and the length of surgery (WMD − 8.20 min, 95% CI (-17.15, 0.74) I2 = 96.28%) did not reach the threshold of statistical significance. Compared to the placebo group, nausea/vomiting was significantly more frequent in the tranexamic acid group (RR 1.89, 95% CI (1.02, 3.52) I2 = 0.00%), while dizziness (RR 1.13, 95% CI (0.32, 3.92) I2 = 16.09%) and headache (RR 1.85, 95% CI (0.48, 7.19) I2 = 25.87%) showed no significant. There was no case of thromboembolic events in either group. Exploratory subgroup analysis showed that sample size, risk of bias, mother’s body mass index (BMI), tranexamic acid dose, the timing of administration, gestational age, and the reason for being high-risk significantly affected the beneficial effects of tranexamic acid on the volume of blood loss.

Conclusion

Our findings suggest that tranexamic acid may effectively reduce bleeding among women with a high risk of postpartum hemorrhage undergoing cesarean section.